RT info:eu-repo/semantics/article
T1 Multiomics insights on the onset, progression, and metastatic evolution of breast cancer
A1 Alvarez-Frutos, Lucia
A1 Barriuso, Daniel
A1 Duran, Mercedes
A1 Infante, Mar
A1 Kroemer, Guido
A1 Palacios-Ramirez, Roberto
A1 Senovilla, Laura
K1 biomarkers; breast cancer; cancer progression; early-stage; metastasis; omics.
AB Breast cancer is the most common malignant neoplasm in women. Despite progress to date, 700,000 women worldwide died of this disease in 2020. Apparently, the prognostic markers currently used in the clinic are not sufficient to determine the most appropriate treatment. For this reason, great efforts have been made in recent years to identify new molecular biomarkers that will allow more precise and personalized therapeutic decisions in both primary and recurrent breast cancers. These molecular biomarkers include genetic and post-transcriptional alterations, changes in protein expression, as well as metabolic, immunological or microbial changes identified by multiple omics technologies (e.g., genomics, epigenomics, transcriptomics, proteomics, glycomics, metabolomics, lipidomics, immunomics and microbiomics). This review summarizes studies based on omics analysis that have identified new biomarkers for diagnosis, patient stratification, differentiation between stages of tumor development (initiation, progression, and metastasis/recurrence), and their relevance for treatment selection. Furthermore, this review highlights the importance of clinical trials based on multiomics studies and the need to advance in this direction in order to establish personalized therapies and prolong disease-free survival of these patients in the future.
PB Frontiers
SN 2234-943X
YR 2023
FD 2023-12-19
LK https://uvadoc.uva.es/handle/10324/66270
UL https://uvadoc.uva.es/handle/10324/66270
LA spa
NO Front Oncol. 2023 Dec 19:13:1292046
NO Producción Científica
DS UVaDOC
RD 28-nov-2024